Abstract
The deprivation gap for breast cancer survival remains unexplained by stage at presentation, treatment, or co-morbidities. We hypothesised that p53 mutation might contribute to the impaired outcome observed in patients from deprived communities. p53 mutation status was determined using the Roche Amplichip research test in 246 women with primary breast cancer attending a single cancer centre and related to deprivation, pathology, overall, and disease-free survival. p53 mutation, identified in 64/246 (26%) of cancers, was most common in 10 out of 17 (58.8%) of the lowest (10th) deprivation decile. Those patients with p53 mutation in the 10th decile had a significantly worse disease-free survival of only 20% at 5 years (Kaplan-Meier logrank chi(2)=6.050, P=0.014) and worse overall survival of 24% at 5 years (Kaplan-Meier logrank chi(2)=6.791, P=0.009) than women of deciles 1-9 with p53 mutation (c.f. 56% and 72%, respectively) or patients in the 10th decile with wild-type p53 (no disease relapse or deaths). p53 mutation in breast cancer is associated with socio-economic deprivation and may provide a molecular basis, with therapeutic implications, for the poorer outcome in women from deprived communities.
References
Sep 1, 1995·Journal of Clinical Pathology·S DetreM Dowsett
Sep 1, 1995·British Journal of Cancer·C T SchrijversM P Coleman
May 4, 1996·BMJ : British Medical Journal·R M MacKie, D J Hole
Oct 24, 1997·Cancer·C T SchrijversJ P Mackenbach
Aug 4, 1998·International Journal of Cancer. Journal International Du Cancer·M SantF Berrino
Mar 25, 2000·The New England Journal of Medicine·P M RidkerN Rifai
Apr 12, 2001·Journal of Epidemiology and Community Health·C S ThomsonUNKNOWN Scottish Cancer Therapy Network
Sep 5, 2001·British Journal of Cancer·C J TwelvesUNKNOWN Scottish Cancer Therapy Network
Jan 9, 2003·Proceedings of the National Academy of Sciences of the United States of America·Lorne J HofsethCurtis C Harris
Aug 14, 2003·British Journal of Cancer·D C McMillanC S McArdle
Sep 1, 1957·British Journal of Cancer·H J BLOOM, W W RICHARDSON
Oct 25, 2003·Journal of Public Health Medicine·Aliki Taylor, K K Cheng
Mar 11, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C S ThomsonUNKNOWN Scottish Cancer Therapy Network
May 20, 2004·British Journal of Cancer·M A MulleeM P Coleman
Aug 12, 2004·British Journal of Cancer·A M Al MurriD C McMillan
Nov 17, 2005·Cancer Research·Frank StaibCurtis C Harris
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Magali OlivierAnne-Lise Børresen-Dale
Mar 16, 2006·Heart·D St J O'ReillyUNKNOWN Midspan and WOSCOPS study groups
May 4, 2006·JAMA : the Journal of the American Medical Association·James BanksJames P Smith
Mar 24, 2007·Nature Reviews. Molecular Cell Biology·Karen H Vousden, David P Lane
Sep 26, 2007·International Journal of Cancer. Journal International Du Cancer·S Perwez Hussain, Curtis C Harris
Oct 1, 2008·British Journal of Cancer·M J QuinnM P Coleman
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brandon L PierceCornelia M Ulrich
Citations
Apr 21, 2012·Pharmacogenomics·Colin McCowan, Alastair M Thompson
Apr 6, 2011·Carcinogenesis·Tiffany A WallaceStefan Ambs
Jun 16, 2011·International Journal of Molecular Sciences·Weiping YeYoung C Lin
Mar 13, 2012·Breast Cancer Research : BCR·Sharon I KingDavid W Meek
Mar 8, 2013·PloS One·Adrienne M StarksStefan Ambs
May 15, 2012·BMC Public Health·Iris PlugJohan P Mackenbach
Dec 5, 2015·Expert Review of Molecular Diagnostics·Akihiro NishiShuji Ogino
May 1, 2015·Cell Cycle·Maria SchwaederleRazelle Kurzrock
Sep 14, 2015·Breast Cancer Research and Treatment·Heather M Ochs-BalcomPeter G Shields
Mar 15, 2014·Cell Cycle·R Sumanth IyerFrances V Fuller-Pace
Jan 22, 2011·Breast Cancer Research : BCR·Jean-Christophe BourdonAlastair M Thompson
Oct 19, 2016·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Ji-Yeon KimYeon Hee Park
Apr 4, 2017·Oncogene·R ShakyaD F Callen
May 24, 2018·Pharmacogenomics·Said El ShamiehFadi Farhat
Aug 19, 2014·FEBS Letters·Jianwei LiShuguang Wang
Apr 2, 2014·The Journal of Pathology·Pavla BouchalovaPhilip J Coates
Jul 30, 2016·Medicine·Xiaosheng Wang, Chittibabu Guda
Jul 1, 2015·PloS One·Matthew J MartonJonathan Cheng
Feb 16, 2013·British Journal of Cancer·J H S DayalA M Thompson
Dec 22, 2011·British Journal of Cancer·C Lo NigroT Crook
Apr 19, 2019·PloS One·Rahmawati PareCheok Soon Lee
Apr 23, 2011·Breast Cancer Research and Treatment·Sandrine BoyaultQing Wang
Jan 6, 2010·Annals of Surgical Oncology·Keith A DookeranSarah Gehlert
Mar 22, 2012·Annals of Surgical Oncology·Keith A DookeranSarah Gehlert
Mar 28, 2013·Annals of Surgical Oncology·Masahisa IshibashiKoshi Mimori
Oct 9, 2019·The Journal of Pathology. Clinical Research·Yajing LiuPhilip J Coates
Jun 11, 2016·Oncotarget·Chung-Hsin ChenYeong-Shiau Pu
Sep 11, 2018·Oncology Letters·Shiyang MaJinhai Wang
Apr 22, 2016·British Journal of Haematology·Francesca MastaglioSudhir Tauro
Dec 21, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Barbara KantorovaSarka Pospisilova
Jun 2, 2018·Annals of Surgical Oncology·Cecilia T OngOluwadamilola M Fayanju